Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABT-101 in advanced solid tumors and HER2 mutated NSCLC
NCT05532696Phase 2Recruiting
- Sponsor
- Anbogen Therapeutics
- Start
- Sep 2022
- Primary completion
- Nov 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ABT-101 in solid tumor and non-small cell lung cancer (NSCLC), sponsored by Anbogen Therapeutics. Primary endpoints: Recommended Phase 2 Dose at 18 months and Objective Response Rate at 36 months. Started Sep 2022; status: recruiting.
02
Drugs
ABT-101
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05532696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05532696.